

CONTENTS

	Page
ACKNOWLEDGEMENTS	i
ABSTRACT	ii
CONTENTS	viii
LIST OF TABLES	xv
LIST OF FIGURES	xvi
LIST OF ABBREVIATIONS	xxi
CHAPTER	
I INTRODUCTION	1
II OBJECTIVES	5
III LITERATURE REVIEW	6
1. INFLUENZA VIRUSES	6
1.1 Morphology and genome of influenza A virus	7
1.2 Influenza A virus life cycle	14
1.3 Influenza virus RNA synthesis	15
1.4 Antigenic variation of the influenza virus	22
1.4.1 Antigenic drift	22
1.4.2 Antigenic shift	22
1.5 Epidemiology of influenza	23
1.6 Diagnosis of influenza	25
1.7 Treatment of influenza by using antiviral drugs	27
1.7.1 The inhibitors of M2 ion channel protein, <i>i.e.</i> , the adamantanes	27
1.7.2 The neuraminidase inhibitors	27
2. INFLUENZA A VIRUS, H5N1 SUBTYPE	28
2.1 Highly pathogenic H5N1 strains	28
2.2 Low pathogenic H5N1	28

CONTENTS (Cont.)

	Page
2.3 Genetic characterization of H5N1 influenza A viruses	29
2.4 Properties of H5N1 influenza virus	29
2.4.1 Infectivity	31
2.4.2 Virulence	34
2.5 Humans and H5N1 influenza virus	35
2.5.1 Symptoms of human influenza caused by avian influenza virus	35
3. THERAPEUTIC ANTIBODY	37
4. ANTIBODY PHAGE DISPLAY LIBRARY	38
4.1 Filamentous phages	39
4.1.1 Structure	39
4.1.2 Life cycle	39
4.1.3 Phagemid cloning vector	41
4.2 Types of ScFv-phage display library	41
4.2.1 Non-immune or single pot library	41
4.2.2 Immune library	42
4.2.3 Synthetic library	42
4.3 Construction of human ScFv phage display library	42
4.4 Selection of antigen-specific ScFv-displaying phage clones	43
4.4.1 Bio-panning with immobilized antigens	45
4.4.2 Bio-panning with antigen in solution	45
4.4.3 Bio-panning with antigen on cells	45
4.4.4 <i>In vivo</i> selection	46
4.5 Expression and purification of human ScFv	46

CONTENTS (Cont.)

	Page
IV MATERIALS AND METHODS	47
1. Avian influenza A virus (H5N1), Thailand isolate and total RNA isolation	47
2. Complementary DNA (cDNA) synthesis	47
3. Primer design for amplification of 5'-halves of PA, PB1 and PB2-coding sequences	48
4. PCR amplification of <i>PA</i> -5', <i>PB1</i> -5' and <i>PB2</i> -5' sequences	50
5. Agarose gel electrophoresis	50
6. Cloning of <i>PA</i> -5', <i>PB1</i> -5', and <i>PB2</i> -5' sequences	50
6.1 DNA purification	50
6.2 Ligation of the <i>PA</i> -5', <i>PB1</i> -5 and <i>PB2</i> -5' sequences to cloning vectors	51
6.3 Preparation of competent cells	51
6.4 Transformation of JM 109 <i>E. coli</i> with the recombinant cloning vectors	52
6.5 Screening of the <i>E. coli</i> clones carrying the recombinant plasmids	52
6.6 Restriction endonuclease digestions of the recombinant plasmids	53
7. Plasmid extraction for DNA sequencing and verification	53
8. DNA sequencing	54
9. Subcloning of <i>PA</i> -5', <i>PB1</i> -5' and <i>PB2</i> -5' sequences into protein expression vectors	54
9.1 Restriction endonuclease digestions of recombinant plasmids and the protein expression vectors	55

CONTENTS (Cont.)

	Page
9.1.1 Recombinant <i>PA-5'</i> -plasmids and the pQE31 protein expression vectors	55
9.1.2 Recombinant <i>PB1-5'</i> -plasmids and the pET-20b(+) protein expression vectors	55
9.1.3 Recombinant <i>PB2-5'</i> -plasmids and the pQE30 protein expression vectors	55
9.2 DNA purification	55
9.3 Ligation of <i>PA-5'</i> , <i>PB1-5'</i> and <i>PB2-5'</i> sequences to the protein expression vectors	56
9.4 Preparation of competent cells	56
9.4.1 Competent JM109 <i>E. coli</i>	56
9.4.2 Competent <i>E. coli</i> BL21(DE3)pLysS cells	56
9.4.3 Competent M15 <i>E. coli</i> cells	57
9.5 Transformation of JM109 <i>E. coli</i> cells which were used as DNA storage host	57
9.5.1 DNA transformation into the JM109 <i>E. coli</i> cells	57
9.5.2 Transformation of the <i>E. coli</i> expression host	58
9.5.2.1 Recombinant <i>PB1-5'</i> -pET-20b(+) plasmids	58
9.5.2.2 Recombinant <i>PB2-5'</i> -pQE30 and <i>PA-5'</i> -pQE31 plasmids	58
10. Recombinant N-terminal PA, N-terminal PB1, and N-terminal PB2 protein expression	59
10.1 Screening of appropriate recombinant <i>E. coli</i> clones for the recombinant protein expression	59
10.2 Large scale expression of the recombinant proteins	60
11. Purification of recombinant polymerase proteins	60

CONTENTS (Cont.)

	Page
11.1 Preparation of cell lysates for purification of the recombinant protein expressed under the natural conformation	60
11.2 Preparing of cell lysates for purification of the recombinant protein expressed under the denatured conformation	61
11.3 Preparation of the Ni-NTA agarose	61
11.4 Purification of the recombinant protein expressed under the natural conformation	61
11.5 Purification of the recombinant protein expressed under denatured conformation	61
12. Protein determination	62
13. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)	62
13.1 Preparation of sample for loading into the slab gel	63
13.2 Electrophoresis	63
13.3 Staining and destaining of protein bands	63
14. Western blot analysis (WB)	63
15. The human antibody phage display library	64
16. Selection of phage clones displaying specific ScFv to the target antigens by “phage bio-panning”	64
17. Screening of HB2151 <i>E. coli</i> clones carrying recombinant phagemids with <i>huscFv</i> insert	65
18. Expression of soluble human monoclonal single chain antibody fragments (HuScFv)	66
19. Detection of binding of the HuScFv to the respective recombinant proteins by indirect ELISA (HuScFv-ELISA)	66
	Page

CONTENTS (Cont.)

	Page
20. Detection of binding of HuScFv to the respective recombinant proteins by immunoblotting	67
21. Detection of binding of HuScFv to the respective recombinant proteins by dot-ELISA	68
22. RFLP patterns of the <i>huscFv</i> sequences	68
23. Functional analysis of the recombinant N-terminal PA	69
23.1 Nuclear import assay using digitonin-permeabilized Vero cells	69
23.1.1 Vero cell culture	69
23.1.2 Nuclear import assay	69
23.1.3 Cell staining and confocal microscopy	70
23.2 RNA binding assay	70
24. Inhibition of nuclear import of the recombinant N-terminal PA by the HuScFv	71
V RESULTS	72
1. Complementary (cDNA) synthesis	72
2. PCR amplification of DNA sequences encoding N-terminal halves of PA, PB1 and PB2 polymerase proteins	72
3. Cloning of DNA sequences encoding N-terminal halves of the PA, PB1 and PB2-polymerases, <i>i.e.</i> , <i>PA-5'</i> , <i>PB1-5'</i> and <i>PB2-5'</i> sequences into cloning vectors	75
4. DNA sequencing	75
5. Subcloning of <i>PA-5'</i> , <i>PB1-5'</i> and <i>PB2-5'</i> sequences into protein expression vectors	81
6. N-terminal PA, PB1 and PB2 protein expression and purification	84
7. Selection of phage clones displaying HuScFv to the polymerase proteins from the phage display human antibody library	94

CONTENTS (Cont.)

	Page
7.1 Phage display human single pot library	94
7.2 Bio-panning	94
8. Screening of transformed HB2151 <i>E. coli</i> clones carrying the <i>huscFv</i> -phagemids	94
9. Screening of HuScFv-expressing transformed HB2151 <i>E. coli</i> clones	97
10. Determination of binding of HuScFv to recombinant proteins by using HuScFv-ELISA, Western blot analysis, and dot ELISA	102
11. Determination of <i>huscFv</i> diversity of the HuScFv by RFLP	107
12. Functional assay of the recombinant N-terminal PA protein	113
12.1 Nuclear import assay	113
12.2 RNA binding assay	113
13. Inhibition of nuclear import of the recombinant N-terminal PA by the HuScFv	116
VI DISCUSSION	118
VII CONCLUSION	126
REFERENCES	128
APPENDIX A	145
APPENDIX B	148
APPENDIX C	152
APPENDIX D	154
APPENDIX E	156
APPENDIX F	161
APPENDIX G	166
APPENDIX H	169
APPENDIX I	171
BIOGRAPHY	173